文献速递糖尿病肥胖与代谢综合征

胰高血糖素原血浆水平的决定因素及胰高血糖素受体信号转导的代谢影响:一项英国生物银行研究

Determinants of plasma levels of proglucagon and the metabolic impact of glucagon receptor signalling: a UK Biobank study.
PubMed 文献 · Diabetologia · 2024-05-06

基于英国生物银行约41万白种人外显子测序及约4万人Olink血浆胰高血糖素原数据,发现肥胖、代谢功能障碍相关脂肪性肝病(MASLD)和2型糖尿病均独立关联血浆胰高血糖素原升高。基线胰高血糖素原与14年随访期间2型糖尿病发生风险相关(HR 1.13;95%CI 1.09,1.17;n=1562;p=1.3×10⁻¹²),且该关联在各BMI分层中幅度相同。胰高血糖素受体变异携带者胰高血糖素原升高,预测移码突变携带者肝脂肪更高。

要点

  • 肥胖、MASLD和2型糖尿病独立关联血浆胰高血糖素原水平升高。
  • 基线胰高血糖素原与14年随访2型糖尿病风险相关(HR 1.13;95%CI 1.09,1.17;p=1.3×10⁻¹²)。
  • 胰高血糖素受体信号转导可能参与MASLD,胰高血糖素原水平受遗传变异等因素影响。

核心结论

  • 研究结果支持胰高血糖素受体信号转导参与MASLD,血浆胰高血糖素原水平与2型糖尿病发生风险相关,且受胰高血糖素受体遗传变异、肥胖、2型糖尿病和MASLD影响。
  • 确定胰高血糖素受体激活下游的分子信号通路可能有助于指导偏向性GLP-1/胰高血糖素双受体激动剂的开发以改善代谢获益。

研究设计与样本

  • 利用英国生物银行约41万白种人参与者的外显子测序数据鉴定胰高血糖素受体变异,并按已知或预测的信号转导进行分组。
  • 约4万参与者有基于Olink技术估算的血浆胰高血糖素原数据。
  • 分析胰高血糖素受体变异和胰高血糖素原与BMI、2型糖尿病及肝脏脂肪(通过肝脏MRI量化)的关联,并进行生存分析以探究胰高血糖素原升高是否预测2型糖尿病发生。

主要发现

  • 肥胖、MASLD和2型糖尿病与血浆胰高血糖素原水平升高独立相关。
  • 基线胰高血糖素原水平与14年随访期间2型糖尿病发生风险相关(HR 1.13;95%CI 1.09,1.17;n=1562;p=1.3×10⁻¹²),该关联在各BMI分层中幅度相同。
  • 携带cAMP信号减弱的胰高血糖素受体变异的参与者胰高血糖素原水平升高(β 0.847;95%CI 0.04,1.66;n=17;p=0.04)。
  • 携带预测移码突变变异的参与者肝脏脂肪较野生型参考组更高(β 0.504;95%CI 0.03,0.98;n=11;p=0.04)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESES: Glucagon and glucagon-like peptide-1 (GLP-1) are derived from the same precursor; proglucagon, and dual agonists of their receptors are currently being explored for the treatment of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). Elevated levels of endogenous glucagon (hyperglucagonaemia) have been linked with hyperglycaemia in individuals with type 2 diabetes but are also observed in individuals with obesity and MASLD. GLP-1 levels have been reported to be largely unaffected or even reduced in similar conditions. We investigated potential determinants of plasma proglucagon and associations of glucagon receptor signalling with metabolic diseases based on data from the UK Biobank. METHODS: We used exome sequencing data from the UK Biobank for ~410,000 white participants to identify glucagon receptor variants and grouped them based on their known or predicted signalling. Data on plasma levels of proglucagon estimated using Olink technology were available for a subset of the cohort (~40,000). We determined associations of glucagon receptor variants and proglucagon with BMI, type 2 diabetes and liver fat (quantified by liver MRI) and performed survival analyses to investigate if elevated proglucagon predicts type 2 diabetes development. RESULTS: Obesity, MASLD and type 2 diabetes were associated with elevated plasma levels of proglucagon independently of each other. Baseline proglucagon levels were associated with the risk of type 2 diabetes development over a 14 year follow-up period (HR 1.13; 95% CI 1.09, 1.17; n=1562; p=1.3×10-12). This association was of the same magnitude across strata of BMI. Carriers of glucagon receptor variants with reduced cAMP signalling had elevated levels of proglucagon (β 0.847; 95% CI 0.04, 1.66; n=17; p=0.04), and carriers of variants with a predicted frameshift mutation had higher levels of liver fat compared with the wild-type reference group (β 0.504; 95% CI 0.03, 0.98; n=11; p=0.04). CONCLUSIONS/INTERPRETATION: Our findings support the suggestion that glucagon receptor signalling is involved in MASLD, that plasma levels of proglucagon are linked to the risk of type 2 diabetes development, and that proglucagon levels are influenced by genetic variation in the glucagon receptor, obesity, type 2 diabetes and MASLD. Determining the molecular signalling pathways downstream of glucagon receptor activation may guide the development of biased GLP-1/glucagon co-agonist with improved metabolic benefits. DATA AVAILABILITY: All coding is available through https://github.com/nicwin98/UK-Biobank-GCG.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Winther-Sørensen M, Garcia SL, Bartholdy A, et al. Determinants of plasma levels of proglucagon and the metabolic impact of glucagon receptor signalling: a UK Biobank study. Diabetologia. 2024. PMID: 38705923. doi:10.1007/s00125-024-06160-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。